Results 171 to 180 of about 895,257 (215)

Clinical outcomes and the impact of treatment modalities in children with carbapenem-resistant Enterobacteriaceae bloodstream infections: a retrospective cohort study from a tertiary university hospital. [PDF]

J Antimicrob Chemother
Avcu G, Erci E, Bilen NM, Ersayoglu I, Ozek G, Celtik U, Terek D, Cilli F, Bal ZS.   +8 more
europepmc   +1 more source

Microbiome Therapeutic Lactiplantibacillus plantarum PMC105 for Systemic Carbapenem-Resistant Enterobacteriaceae Infections: Oral and Inhalation Efficacy In Vivo. [PDF]

J Microbiol Biotechnol
Sarafraz F, Seo H, Tajdozian H, Atashi A, Yoon Y, Kim S, Song HY.   +6 more
europepmc   +1 more source

Challenges of Carbapenem-Resistant <i>Enterobacteriaceae</i> in the Development of New β-Lactamase Inhibitors and Antibiotics. [PDF]

Antibiotics (Basel)
Leroux P, Bornet C, Bolla JM, Cohen A.
europepmc   +1 more source

Clonal transmission and species-specific mechanisms of polymyxin resistance in carbapenem-resistant <i>Enterobacteriaceae</i> from Southwest China. [PDF]

Front Cell Infect Microbiol
Si T, Liu H, Xia P, Huang N, Tang S, Li Y, Han Q, Song Y, Liu Y, Xia Y.   +9 more
europepmc   +1 more source

Antimicrobial and Anti-Biofilm Activity of Dichlorophen-Functionalized Gold Nanoparticles Against Carbapenem-Resistant <i>Enterobacteriaceae</i>. [PDF]

Int J Nanomedicine
Hu P, Chen H, Qian C, Fu Q, Zhang S, Huang Z, Liu H, Zhou C, Shen M, Zhou T.   +9 more
europepmc   +1 more source

Systematic Review and Meta-Analysis of Clinical Efficacy and Safety of Meropenem-Vaborbactam versus Best-Available Therapy in Patients with Carbapenem-Resistant Enterobacteriaceae Infections. [PDF]

Int J Mol Sci
Bucataru A, Turcu-Stiolica A, Calina D, Balasoiu AT, Zlatian OM, Osman A, Balasoiu M, Ghenea AE.   +7 more
europepmc   +1 more source